Head to Head Review: Chiasma (CHMA) vs. Its Peers
Chiasma (NASDAQ: CHMA) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Chiasma to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, risk, earnings, valuation and profitability.
This is a breakdown of current recommendations and price targets for Chiasma and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biopharmaceuticals” companies have a potential upside of 7.69%. Given Chiasma’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Chiasma has less favorable growth aspects than its competitors.
Risk and Volatility
Chiasma has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Chiasma’s competitors have a beta of 1.24, meaning that their average stock price is 24% more volatile than the S&P 500.
Earnings and Valuation
This table compares Chiasma and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Chiasma Competitors||$579.33 million||$241.73 million||-6.56|
Chiasma’s competitors have higher revenue and earnings than Chiasma. Chiasma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Chiasma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
50.4% of Chiasma shares are held by institutional investors. Comparatively, 44.6% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 3.2% of Chiasma shares are held by insiders. Comparatively, 14.0% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Chiasma competitors beat Chiasma on 9 of the 12 factors compared.
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.